Literature DB >> 1097046

Double-blind evaluation of mazindol in refractory obesity.

R G Smith, J A Innes, J F Munro.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1097046      PMCID: PMC1674216          DOI: 10.1136/bmj.3.5978.284

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


× No keyword cloud information.
  1 in total

1.  Comparison of a new anorectic agent AN 448 with fenfluramine in the treatment of refractory obesity.

Authors:  R B Goldrick; P J Nestel; N Havenstein
Journal:  Med J Aust       Date:  1974-06-01       Impact factor: 7.738

  1 in total
  4 in total

1.  Endocrine and metabolic disease. Obesity.

Authors:  J F Munro
Journal:  Br Med J       Date:  1976-02-14

Review 2.  The role of drugs in the treatment of obesity.

Authors:  J G Douglas; J F Munro
Journal:  Drugs       Date:  1981-05       Impact factor: 9.546

Review 3.  Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients.

Authors:  Rosa Camila Lucchetta; Bruno Salgado Riveros; Roberto Pontarolo; Rosana Bento Radominski; Michel Fleith Otuki; Fernando Fernandez-Llimos; Cassyano Januário Correr
Journal:  Clinics (Sao Paulo)       Date:  2017-05       Impact factor: 2.365

4.  A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD).

Authors:  Tim L Wigal; Jeffrey H Newcorn; Nelson Handal; Sharon B Wigal; Ioulietta Mulligan; Virginia Schmith; Eric Konofal
Journal:  CNS Drugs       Date:  2018-03       Impact factor: 5.749

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.